Guided internet-based treatment for individuals with harmful alcohol use, eBehandling Alkohol (eBA), will be implemented as an experimental treatment option in five hospitals autumn 2024. Concurrently, a research project related to the effects of eBA will be conducted. Results from a pilot project show that treatment with eBA can help reduce alcohol use and improve mental health among people with harmful alcohol consumption. Similar results have been found in other international studies. Many individuals with harmful alcohol consumption avoid seeking treatment, leading to negative consequences for the individual, their families, and society. The pilot project indicates that guided internet-based treatment is an effective treatment that is easily accessible and cost-effective. Access to eBA can help circumvent shame and stigma, increase access to treatment, reduce alcohol use, and improve physical and mental health. Individuals who wish to participate in eBA do not need a referral from a GP. After an initial screening, participants will be given access to eBA, which consists of 9 treatment modules to be completed over an 8-12-week period, upon giving their consent. Participants will be followed up 4 weeks, 6 months, and 2 years after the completion of treatment. Data will be collected during screening, throughout the treatment period, and post-treatment. Data will be collected in the form of questionnaires, interviews, and registry data. Simultaneously with the implementation of eBA as an experimental treatment, this project aims to investigate the characteristics of participants who apply for eBA, as well as examine the effects eBA may have in terms of reducing alcohol use, improving physical and mental health, and enhancing the quality of life among participants. The overarching goal of the study is to strengthen the understanding of the effects of internet-based treatment, thereby providing a sufficient basis to assess whether eBA should be implemented as a regular treatment option. The study will also be part of a larger collaborative project where we will conduct meta-analyses of results from eBA and two other studies that also include treatment programs aimed at individuals with varying degrees of alcohol problems: the "Predictor Study" and "Endre". The three treatment programs are aimed at individuals who are at different stages in their problem trajectory. The goal of this collaborative project is to contribute to the development of a more holistic and targeted treatment offer for individuals with varying degrees of problem development.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Identifying characteristics of people seeking eBA
Timeframe: Baseline measure
Changes in alcohol use
Timeframe: Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Changes in mental health status
Timeframe: Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Changes in mental health status
Timeframe: Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Changes in quality of life
Timeframe: Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment
Changes in quality of life
Timeframe: Measure changes from baseline to end of treatment, and 6 months and 2 years post-treatment